<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002839</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-24954</org_study_id>
    <nct_id>NCT00002839</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Plus Radiation Therapy To Preserve the Larynx in Patients With Cancer of the Hypopharynx or Larynx</brief_title>
  <official_title>PHASE II STUDY ON LARYNX PRESERVATION COMPARING INDUCTION CHEMOTHERAPY AND RADIOTHERAPY VERSUS ALTERNATING CHEMO-RADIOTHERAPY IN RESECTABLE HYPOPHARYNX AND LARYNX CANCERS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
      Combining chemotherapy with radiation therapy may kill more tumor cells and allow doctors to
      preserve the part of the body where the cancer started. It is not yet known which regimen of
      cisplatin and fluorouracil combined with radiation therapy is more effective in treating
      resectable cancer of the hypopharynx or larynx.

      PURPOSE: Randomized phase III trial to compare the effectiveness of two regimens of cisplatin
      and fluorouracil combined with radiation therapy in preserving the larynx in patients who
      have resectable cancer of the hypopharynx or larynx.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare relapse-free survival and larynx preservation in patients with resectable
           hypopharyngeal or laryngeal cancer treated with sequential vs alternating cisplatin and
           fluorouracil and radiotherapy.

        -  Compare the health-related quality of life in patients treated with these regimens.

        -  Compare the cost-effectiveness of these regimens.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified by performance
      status, disease site, tumor stage, node stage, and center.

      Patients are randomized to one of two treatment arms. Both groups may receive either
      conventional radiotherapy in single daily fractions, 5 days per week, for 7 weeks (option 1)
      or hyperfractionated radiotherapy in 2 daily fractions, 5 days per week, for 4-5 weeks
      (option 2), according to institutional policy.

        -  Arm I: Patients receive cisplatin and fluorouracil every 3 weeks. Patients with a
           complete or partial response on day 42 receive 2 additional courses of chemotherapy
           followed by 7 weeks of radiotherapy beginning on day 80. After radiotherapy, patients
           with a complete remission enter follow-up; those with a partial remission proceed to
           surgery. Patients with stable or progressive disease proceed immediately to surgery with
           or without postoperative radiotherapy.

        -  Arm II: Patients receive cisplatin and fluorouracil every 3 weeks for 4 courses.
           Patients treated on radiotherapy option 1 are evaluated 2 months after completion of
           radiotherapy; those with a complete remission enter follow-up while all others proceed
           to surgery. Patients treated on option 2 are evaluated on day 42; those with a partial
           or complete response complete chemoradiotherapy and are then evaluated and treated like
           option 1 patients. Patients with stable or progressive disease on day 42 proceed to
           surgery with or without a third course of chemotherapy on week 7.

      Patients are followed every 3 months for 3 years and at least every 6 months thereafter.

      PROJECTED ACCRUAL: A total of 564 patients will be accrued for this study within 4 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1996</start_date>
  <primary_completion_date type="Actual">May 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">564</enrollment>
  <condition>Head and Neck Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically proven squamous cell carcinoma of the head and neck, including:

               -  Stage III/IV cancer of the glottic or supraglottic larynx

                    -  Eligible T4 tumor defined as:

                         -  Bulging the valleculae

                         -  Bulging the hyothyroid membrane

                         -  Minimal thyroid cartilage invasion or suspicion of invasion on imaging

               -  Stage II/III/IV cancer of the pyriform sinus or of the hypopharyngeal aspect of
                  the aryepiglottic fold (with or without extension to postcricoid area)

                    -  No massive destruction of the thyroid cartilage

                    -  No continuity between primary tumor and a lymph node

          -  Operable on first attempt (as assessed by head and neck surgeon) by classical total
             laryngectomy with or without partial pharyngectomy

               -  No requirement for extended surgery (circumferential pharyngolaryngectomy)

               -  No tumor suitable for partial (functional) surgery or requiring extended surgery
                  that necessitates any kind of flap for closure

               -  No N2c tumor unless no requirement for bilateral resection of internal jugular
                  veins

          -  Measurable or evaluable disease by panendoscopy and CT scan or MRI

               -  Esophagoscopy required

               -  Bronchofiberscopy recommended

          -  No requirement for tracheotomy

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  ECOG 0-2 OR

          -  WHO 0-2

        Hematopoietic:

          -  WBC at least 4,000/mm^3

        Hepatic:

          -  Bilirubin no greater than 2.0 times normal

        Renal:

          -  Creatinine no greater than 1.5 mg/dL OR

          -  Creatinine clearance at least 60 mL/min

        Other:

          -  No medical, psychological, or geographical condition that precludes study compliance

          -  No serious nonmalignant systemic disease

          -  No second malignancy except:

               -  Carcinoma in situ of the cervix

               -  Adequately treated nonmelanomatous skin cancer

          -  No poor nutritional status unlikely to be restored to fair status within 3 weeks

          -  No contraindication to CT scan or general anesthesia

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No prior anticancer biologic therapy

        Chemotherapy

          -  No prior anticancer chemotherapy

        Endocrine therapy

          -  No prior anticancer endocrine therapy

        Radiotherapy

          -  No prior anticancer radiotherapy

        Surgery

          -  See Disease Characteristics

        Other

          -  No other prior anticancer therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Louis Lefebvre, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Claude Horiot, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Georges Francois Leclerc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Algemeen Ziekenhuis Middelheim</name>
      <address>
        <city>Antwerp</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR de Besancon - Hopital Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Lutte Contre le Cancer, Georges-Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional et Universitaire de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRLCC Nantes - Atlantique</name>
      <address>
        <city>Nantes-Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale per lo Studio e la Cura dei Tumori</name>
      <address>
        <city>Milano (Milan)</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Monselice</name>
      <address>
        <city>Monselice, Padova</city>
        <zip>35043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera &quot;Santa Maria Degli Angeli&quot;</name>
      <address>
        <city>Pordenone</city>
        <zip>33170</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vrije Universiteit Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1007 MB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Maastricht</name>
      <address>
        <city>Maastricht</city>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Lefebvre JL, Rolland F, Tesselaar M, Bardet E, Leemans CR, Geoffrois L, Hupperets P, Barzan L, de Raucourt D, Chevalier D, Licitra L, Lunghi F, Stupp R, Lacombe D, Bogaerts J, Horiot JC, Bernier J, Vermorken JB; EORTC Head and Neck Cancer Cooperative Group; EORTC Radiation Oncology Group. Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst. 2009 Feb 4;101(3):142-52. doi: 10.1093/jnci/djn460. Epub 2009 Jan 27.</citation>
    <PMID>19176454</PMID>
  </results_reference>
  <results_reference>
    <citation>Lefebvre J, Horiot J, Rolland F, et al.: Phase III study on larynx preservation comparing induction chemotherapy and radiotherapy versus alternating chemoradiotherapy in resectable hypopharynx and larynx cancers. EORTC protocol 24954-22950. [Abstract] J Clin Oncol 25 (Suppl 18): A-LBA6016, 303s, 2007.</citation>
  </results_reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 7, 2013</last_update_submitted>
  <last_update_submitted_qc>January 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the larynx</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Laryngeal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

